What Is Fatty Liver Disease and Why Is It So Common?
Fatty liver disease, now called MASLD, silently affects nearly one in three adults worldwide. Here is how it develops, why it often goes undetected, and what science says about reversing it.
A Silent Epidemic Hiding in Plain Sight
More than 30 percent of adults worldwide carry excess fat in their liver, yet most have no idea. Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as nonalcoholic fatty liver disease (NAFLD) — has become the most common chronic liver condition on the planet. In the United States alone, estimates suggest that between 80 and 100 million people are affected.
Because the disease rarely causes symptoms in its early stages, many patients learn about it only after routine blood work or an imaging scan reveals the problem. Understanding how MASLD develops, who is at risk, and what can be done about it is increasingly important as global obesity and diabetes rates continue to climb.
How Fat Accumulates in the Liver
A healthy liver contains a small amount of fat. Trouble begins when fat deposits exceed roughly five percent of the organ's weight. The liver, which normally processes and exports fats, starts storing more than it can handle. Over time, this imbalance triggers inflammation and, in some patients, scarring known as fibrosis.
The disease exists on a spectrum. Simple steatosis — fat without significant inflammation — is the mildest form. About 20 percent of cases progress to metabolic dysfunction-associated steatohepatitis (MASH), where ongoing inflammation damages liver cells and stimulates scar-tissue formation. Left unchecked, MASH can advance through stages of fibrosis until it reaches cirrhosis, a state of irreversible scarring that can lead to liver failure or liver cancer.
Each fibrosis stage takes an average of roughly seven years to develop, according to Cleveland Clinic, which means the disease often unfolds over decades before causing serious harm.
Who Is at Risk?
MASLD is tightly linked to the metabolic syndrome — a cluster of conditions that includes obesity, type 2 diabetes, high blood pressure, and abnormal cholesterol levels. Among people with type 2 diabetes, the estimated prevalence of fatty liver disease ranges from 55 to 70 percent, according to the American Diabetes Association.
Ethnicity also plays a role. Research from Virginia Commonwealth University found that Hispanic adults have a higher prevalence — roughly 47 percent — compared with about 40 percent in the general adult population. Genetic variations, particularly in the PNPLA3 gene, further influence individual susceptibility.
Crucially, MASLD is not restricted to people who are overweight. Up to 20 percent of patients with the condition have a normal body mass index, a subgroup sometimes called "lean MASLD."
Why It Often Goes Undetected
Fatty liver disease earns its reputation as a "silent" condition because early stages produce few or no symptoms. When symptoms do appear, fatigue is the most common complaint, sometimes accompanied by vague upper-abdominal discomfort. By the time more obvious signs emerge — fluid retention, jaundice, or confusion — the disease has usually progressed to cirrhosis.
There is no routine screening recommendation for the general population. Diagnosis typically relies on elevated liver enzymes in blood tests, ultrasound imaging, or specialized techniques like FibroScan, which measures liver stiffness as a proxy for fibrosis.
Treatment: Lifestyle First
No drug has yet been universally approved as a cure for MASLD, making lifestyle modification the cornerstone of treatment. According to the Mayo Clinic, losing just five percent of body weight can measurably reduce liver fat, while a seven-to-ten-percent loss can ease inflammation and begin to reverse fibrosis.
Dietary guidance centres on the Mediterranean diet — rich in vegetables, whole grains, olive oil, and fatty fish — while limiting processed foods, added sugars, and saturated fats. At least 150 minutes of moderate-intensity exercise per week is recommended, as physical activity reduces liver fat even before significant weight loss occurs.
Research is also advancing on the pharmaceutical front. A 2025 study published in the journal Metabolism identified microRNA-93 as a key genetic driver of MASLD and found that niacin (vitamin B3) effectively suppresses it in animal models, raising hopes for an inexpensive future treatment — though clinical trials in humans are still needed.
Why It Matters
MASLD is already the fastest-growing indication for liver transplantation in several countries. As obesity rates rise globally — particularly among younger populations — the disease is poised to become an even larger public-health burden. Early awareness, metabolic health screening, and simple lifestyle adjustments remain the most powerful tools available to slow the epidemic before it overwhelms healthcare systems.
